Published in Transplantation on March 27, 2013
Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. Br J Clin Pharmacol (2014) 0.92
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol (2014) 0.90
Role of endoplasmic reticulum stress in drug-induced toxicity. Pharmacol Res Perspect (2016) 0.86
Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients. Bioimpacts (2015) 0.85
Neurovascular unit in chronic pain. Mediators Inflamm (2013) 0.80
Role of pharmacogenomics in dialysis and transplantation. Curr Opin Nephrol Hypertens (2014) 0.78
Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis (2014) 0.77
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1979) 6.10
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Cyclosporine-associated chronic nephropathy. N Engl J Med (1984) 3.39
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol (2009) 3.33
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther (2003) 2.09
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics (2004) 2.06
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol (2002) 1.91
Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther (2008) 1.74
Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev (1997) 1.47
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet (2010) 1.46
Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos (1995) 1.39
ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol (2005) 1.21
Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet (2010) 1.20
ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics (2003) 1.13
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther (2004) 1.10
Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc (2005) 1.09
In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol (2004) 1.06
Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol (1996) 1.04
Cyclosporin metabolism in transplant patients. Pharmacol Ther (1993) 0.99
Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics (2003) 0.95
A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation (2004) 0.91
CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit (2004) 0.88
CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J (2008) 0.88
Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther (2012) 0.86
Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit (1997) 0.85
No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant (2008) 0.84
Determination of cyclosporine and its metabolites in blood via HPLC-MS and correlation to clinically important parameters. Transplant Proc (2005) 0.84
Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation (1992) 0.83
Association between renal function and CYP3A5 genotype in heart transplant recipients treated with calcineurin inhibitors. J Heart Lung Transplant (2010) 0.83
Ciclosporin metabolite pattern in blood and urine of liver graft recipients. I. Association of ciclosporin metabolites with nephrotoxicity. Eur J Clin Pharmacol (1991) 0.82
Deposition of nine metabolites of cyclosporine in human tissues, bile, urine, and whole blood. Transplant Proc (1988) 0.80
Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc (2008) 0.80
Toxicity of cyclosporine metabolites. Ther Drug Monit (1990) 0.79
The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int (2006) 0.79
Inhibition of esterolysis of enalapril by paraoxon increases the urinary clearance in isolated perfused rat kidney. Drug Metab Dispos (1999) 0.79
Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy. Transplant Proc (2001) 0.78
Studies of cyclosporine and metabolite toxicity in renal and hepatocyte culture systems. Transplant Proc (1990) 0.77
The bumpy road of genomic medicine in transplantation: lessons from studies on calcineurin inhibitor nephrotoxicity. Transplantation (2012) 0.76
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev (2002) 3.73
Racial variation in medical outcomes among living kidney donors. N Engl J Med (2010) 3.60
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue. PLoS Genet (2011) 2.68
Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest (2006) 2.28
Implementing practical interventions to support chronic illness self-management. Jt Comm J Qual Saf (2003) 2.08
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther (2006) 1.98
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol (2002) 1.91
Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol (2008) 1.76
Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest (2006) 1.75
Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl (2009) 1.69
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther (2004) 1.67
Genetic polymorphisms in the catechol estrogen metabolism pathway and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2009) 1.62
Characterizing antibody cross-reactivity for immunoaffinity purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry. Clin Chem (2012) 1.52
Kidney transplant chains amplify benefit of nondirected donors. JAMA Surg (2013) 1.52
Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant (2005) 1.52
Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos (2004) 1.52
The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol (2006) 1.47
Determination of free and total cortisol in plasma and urine by liquid chromatography-tandem mass spectrometry. Ther Drug Monit (2007) 1.47
Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol (2008) 1.45
Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos (2007) 1.43
Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect (2005) 1.42
Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol (2011) 1.36
Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther (2008) 1.34
Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol (2005) 1.33
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics (2002) 1.30
Predictors of ARF after cardiac surgical procedures. Am J Kidney Dis (2003) 1.28
Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos (2013) 1.27
The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: an Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol (2007) 1.26
Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos (2006) 1.26
Profiling gene expression in human placentae of different gestational ages: an OPRU Network and UW SCOR Study. Reprod Sci (2008) 1.25
Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos (2004) 1.25
Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation. Am J Obstet Gynecol (2012) 1.22
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos (2006) 1.22
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos (2004) 1.20
An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol (2011) 1.18
Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther (2004) 1.18
Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology (2007) 1.16
Developing a prototype system for integrating pharmacogenomics findings into clinical practice. J Pers Med (2012) 1.15
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
Ibuprofen arginate provides effective relief from postoperative dental pain with a more rapid onset of action than ibuprofen. Eur J Clin Pharmacol (2002) 1.10
Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos (2010) 1.09
Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos (2011) 1.08
The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics. Br J Clin Pharmacol (2012) 1.07
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther (2006) 1.06
In vitro metabolism of cyclosporine A by human kidney CYP3A5. Biochem Pharmacol (2004) 1.06
Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. J Am Soc Nephrol (2010) 1.06
Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. J Pharmacol Exp Ther (2004) 1.05
Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol (2009) 1.05
Down-regulation of hepatic transporters for BSP in rats with indomethacin-induced intestinal injury. Biol Pharm Bull (2007) 1.05
Simultaneous measurement of plasma vitamin D(3) metabolites, including 4β,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry. Anal Biochem (2011) 1.04
CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology (2003) 1.02
MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS (2005) 1.02
Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant (2004) 1.00
Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos (2011) 0.98
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother Pharmacol (2006) 0.97
Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos (2010) 0.96
Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia. J Bone Miner Res (2013) 0.96
Zonula Occludens-1 alterations and enhanced intestinal permeability in methotrexate-treated rats. Cancer Chemother Pharmacol (2010) 0.95
CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos (2010) 0.95
Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos (2010) 0.95
Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics (2008) 0.95
Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics (2003) 0.95
Transplantation in the diabetic patient with advanced chronic kidney disease: a task force report. Am J Kidney Dis (2004) 0.95
Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr (2010) 0.95
Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos (2006) 0.94
Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos (2013) 0.94
Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol (2003) 0.94